A new report found only about 2.8% of people with myelodysplastic syndromes (MDS) have JAK2 mutations.

Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation is a change in the gene that can cause uncontrolled blood ...

JAK2 V617F mutation: A recurrent somatic point mutation in the Janus kinase 2 gene that leads to constitutive activation of proliferative signalling pathways in myeloproliferative neoplasms.

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

The mutation is associated with about 25% of myelofibrosis cases. Most studies have shown that JAK2, MPL, and CALR are mutually exclusive and do not occur together.

What is the JAK2 gene and what role does it play in certain conditions? Read on to learn more about this gene and how certain variation can result in health conditions.

WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...